Dr. Bleck will discuss how Catalent’s proprietary GPEx® technology, a versatile protein expression system capable of transferring genes of interest into a wide variety of mammalian host cells, was assessed to see how IgG allotype or subclasses impacted cell line productivity and the efficiency of this protein manufacturing process. For more information on this event, please visit: http://www.meetingsmanagement.com/hah_2011.
For an interview with Dr. Bleck, please contact Patricia McGee or Chris Halling at media@catalent.com.
Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics. He has a broad background in Molecular Biology and Transgenic animals with 12 year’s experience within the organization. Dr. Bleck holds a Bachelor’s degree in Dairy Science and a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Greg has published more than 55 research papers and co-authored chapters in three books.
About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ. For more information, visit www.catalent.com.
more products. better treatments. reliably supplied.™
Media Contacts:
Chris Halling at +44 (0) 7580 041073 or Patricia McGee at +1 732 537 6407
media@catalent.com
